Wolverine Blend (BPC-157/TB500) 10mg

The Wolverine Blend combines the two most extensively studied tissue-repair peptides in complementary research: BPC-157 and TB-500 (thymosin beta-4). The blend name references the fictional character's regenerative abilities, reflecting the synergistic healing potential suggested by the combined research profiles of these peptides. BPC-157 acts primarily through pro-angiogenic mechanisms — it upregulates VEGF, EGF, and their receptors to promote new blood vessel formation at injury sites. It also modulates the nitric oxide system and the FAK-paxillin pathway critical for cell adhesion and migration during wound repair. Its effects have been demonstrated across tendon, ligament, muscle, bone, skin, and gastrointestinal tissues in over 100 animal studies. TB-500 acts through a complementary mechanism centered on actin biology. By sequestering G-actin monomers, TB-500 regulates the pool of actin available for polymerization, which directly controls cell migration speed. Since cell migration into wound beds is often the rate-limiting step in tissue repair, TB-500 effectively removes this bottleneck. It additionally provides anti-inflammatory activity through NF-kB suppression and promotes cardiomyocyte survival through Akt activation. The rationale for combining these peptides is that they address different stages and requirements of the healing cascade: BPC-157 establishes the vascular supply needed for repair, while TB-500 accelerates the cellular migration that populates the repair site. Together, they create conditions for faster, more complete tissue regeneration than either alone.

The Wolverine Blend combines the two most extensively studied tissue-repair peptides in complementary research: BPC-157 and TB-500 (thymosin beta-4). The blend name references the fictional character's regenerative abilities, reflecting the synergistic healing potential suggested by the combined research profiles of these peptides. BPC-157 acts primarily through pro-angiogenic mechanisms — it upregulates VEGF, EGF, and their receptors to promote new blood vessel formation at injury sites. It also modulates the nitric oxide system and the FAK-paxillin pathway critical for cell adhesion and migration during wound repair. Its effects have been demonstrated across tendon, ligament, muscle, bone, skin, and gastrointestinal tissues in over 100 animal studies. TB-500 acts through a complementary mechanism centered on actin biology. By sequestering G-actin monomers, TB-500 regulates the pool of actin available for polymerization, which directly controls cell migration speed. Since cell migration into wound beds is often the rate-limiting step in tissue repair, TB-500 effectively removes this bottleneck. It additionally provides anti-inflammatory activity through NF-kB suppression and promotes cardiomyocyte survival through Akt activation. The rationale for combining these peptides is that they address different stages and requirements of the healing cascade: BPC-157 establishes the vascular supply needed for repair, while TB-500 accelerates the cellular migration that populates the repair site. Together, they create conditions for faster, more complete tissue regeneration than either alone.

Research protocols typically reference individual component studies. BPC-157: 10 mcg/kg in animal models. TB-500: 10 mg loading dose protocols in equine research. Blend ratios are optimized per formulation.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.